Comparison of commercial antimicrobial susceptibility test methods for testing of staphylococcus aureus and enterococci against vancomycin, daptomycin, and linezolid

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 2216-2222

  Riedel, Stefan ^a,b   Neoh, Kar Mun ^a   Eisinger, Stephen W ^a   Dam, Lisa M ^b   Tekle, Tsigereda ^c   Carrolla, Karen C ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH DILUTION; COMMERCIAL PHENOMENA; CONTROLLED STUDY; ENTEROCOCCUS; EPSILOMETER TEST; INTERMETHOD COMPARISON; MICROBIOLOGY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENTEROCOCCUS; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84901660833     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00957-14     Document Type: Article

References (36)

1. Khatib R, Sharma M, Iyer S, Fakih MG, Obeid KM, Venugopal A, Fishbain J, Johnson LB, Segireddy M, Jose J, Riederer K. 2013. Decreasing incidence of Staphylococcus aureus bacteremia over 9 years: greatest decline in community-associated methicillin-susceptible and hospitalacquired methicillin-resistant isolates. Am. J. Infect. Control 41:210-213. http://dx.doi.org/10.1016/j.ajic.2012.03.038.
2. Klein EY, Sun L, Smith DL, Laxminarayan R. 2013. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am. J. Epidemiol. 177:666-674. http://dx.doi.org/10.1093/aje/kws273.
3. Kullar R, Rybak MJ, Kaye KS. 2013. Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a prospective score analysis. Infect. Control Hosp. Epidemiol. 34:400-406. http://dx.doi.org/10.1086/669868.
4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/ jama.298.15.1763.
5. Diekema DJ, Richter SS, Heilmann KP, Dohrn CL, Riahi F, Tendolkar S, McDanel JS, Doern GV. 2014. Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study. Infect. Control Hosp. Epidemiol.35,285-292 http://dx.doi.org/10.1086/675283
6. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
7. CLSI. 2012. Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Tenover FC, Moellering RC, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. http://dx.doi.org/10.1086/513203. (Pubitemid 46651246)
9. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. 2011. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int. J. Antimicrob. Agents 37:219-224. http://dx.doi.org/10.1016/j.ijantimicag.2010.10. 029.
10. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54: 755-771. http://dx.doi.org/10.1093/cid/cir935.
11. Holmes RL, Jorgensen JH. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52:757-760. http://dx.doi.org/10.1128/AAC. 00945-07. (Pubitemid 351170860)
12. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stallrecht K. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52: 3315-3320. http://dx.doi.org/10.1128/AAC.00113-08.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch. Intern. Med. 166:2138-2144. http://dx.doi.org/10.1001/archinte.166.19. 2138. (Pubitemid 44631403)
14. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with high vancomycin minimum inhibitory concentration: a case-control study. Clin. Infect. Dis.54; 51-58. http://dx.doi.org/10.1093/cid/cir764
15. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ.2013. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration- 1 mg/L: a matched cohort study. Clin. Infect. Dis. 56: 1562-1569. http://dx.doi.org/10.1093/cid/cit112.
16. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: e18-e55. http://dx.doi.org/10.1093/ cid/ciq146.
17. Toyokawa M, Francisco M, Nishi I, Sunada A, Ueda A, Sakata T, Kimura K, Inoue Y, Asari S, Tomono K. 2011. Accuracy of commercial susceptibility testing method for measuring vancomycin MIC against methicillin-resistant Staphylococcus aureus (MRSA). Lab. Med. 42:473-477. http://dx.doi.org/10.1309/ LM9HB2LB2AORIATX.
18. Riedel S, Eisinger SW, Schwartz M, Dam LM, Tekle T, Carroll KC. 2012. Comparison of various commercially available antimicrobial susceptibility test methods for assessment of MIC values for vancomycin, daptomycin, linezolid, and quinupristin-dalfopristin against Staphylococcus aureus and enterococci. Abstr. 112th Gen. Meet. Am. Soc. Microbiol., abstr C 4386.
19. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Turnidge, J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06. (Pubitemid 47175010)
21. Nadarajah R, Post LR, Lui C, Miller SA, Sahm DF, Brooks GF. 2010. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre system and the MicroScan system. Am. J. Clin. Pathol. 133:844-848. http://dx.doi.org/10.1309/AJCPMV1P0VKUAZRD.
22. Sader HS, Romberg PR, Jones RN. 2009. Nine-hospital study comparing broth microdilutionandE-testmethodresults for vancomycinanddaptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.53;3162-3165 http://dx.doi.org/10.1128/AAC.00093-09
23. Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago BM, Carey RB, Tenover FC, Patel JB. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47: 2013-2017. http://dx.doi.org/10. 1128/JCM.00221-09.
24. Jevitt LA, Thorne GM, Traczewski MM, Jones RN, McGowan JE, Tenover FC, Brown SD. 2006. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J. Clin. Microbiol.44;3098-3104, http://dx.doi.org/10.1128/JCM.00665-06 (Pubitemid 44413737)
25. Friedrich L, Thorne G, Steenbergen JN, Anastasiou D, Koeth L. 2009. Evidence for daptomycin Etest lot-related MIC elevations for Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 65:306-311. http://dx.doi.org/10.1016/j. diagmicrobio.2009.07.012.
26. Tenover FC, Williams PP, Stocker S, Thompson A, Clark LA, Limbago B, Carey RB, Poppe SM, Shinabarger D, McGowan JE, Jr. 2007. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45:2917-2922. http://dx.doi.org/10.1128/ JCM.00913-07. (Pubitemid 47417334)
27. Carroll KC, Borek AP, Burger C, Glanz B, Bhally H, Henciak S, Flayhart DC. 2006. Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of staphylococci and enterococci. J. Clin. Microbiol. 44:2072-2077. http://dx.doi.org/10.1128/JCM. 02636-05. (Pubitemid 43902155)
28. Bryant KA, Roberts AL, Rupp ME, Anderson JA, Lyden ER, Fey PD, van Schooneveld TC. 2013. Susceptibility of enterococci to daptomycin is dependent upon testing methodology. Diagn. Microbiol. Infect. Dis. 76:497-501. http://dx.doi.org/10.1016/j.diagmicrobio.2013.04.019.
29. Bobenchik AM, Hindler JA, Giltner CL, Saeki S, Humphries RM. 2014. Performance of the Vitek2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp. J. Clin. Microbiol. 52:392-397. http://dx.doi.org/10.1128/JCM.02432-13.
30. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillinresistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.51;2582-2586.http://dx.doi.org/10.1128/AAC.00939-06 (Pubitemid 47047340)
31. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. http://dx.doi.org/10.1086/524667. (Pubitemid 351269157)
32. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infection. Int. J. Antimicrob. Agents 32:378-385. http://dx.doi.org/10.1016/j.ijantimicag.2008.05. 007.
33. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. 2012. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.56:5164-5170. http://dx.doi.org/10.1128/AAC.00757-12.
34. King EA, McCoy D, Desani S, Nyirenda T, Bicking K. 2011. Vancomycin-resistant enterococcal bacteremia and daptomycin: are higher doses necessary? J. Antimicrob. Chemother. 66:2112-2118. http://dx.doi.org/10.1093/ jac/dkr255.
35. Forstner C, Dungl C, Tobudic S, Mitteregger D, Lagler H, Burgmann H. 2013. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin. Microbiol. Infect. 19:E291-E297. http://dx.doi.org/10.1111/1469-0691.12169.
36. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. 2006. Casecontrol study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216. http://dx.doi.org/10.1016/j.clinthera. 2006.08.003.